Great Lakes Advisors LLC Sells 6,000 Shares of Edwards Lifesciences Corp (EW)

Great Lakes Advisors LLC cut its stake in Edwards Lifesciences Corp (NYSE:EW) by 13.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 37,429 shares of the medical research company’s stock after selling 6,000 shares during the quarter. Great Lakes Advisors LLC’s holdings in Edwards Lifesciences were worth $6,516,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Honkamp Krueger Financial Services Inc. acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $106,000. Private Capital Group LLC acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $112,000. Centaurus Financial Inc. acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $114,000. SRS Capital Advisors Inc. increased its position in shares of Edwards Lifesciences by 317.5% during the 3rd quarter. SRS Capital Advisors Inc. now owns 668 shares of the medical research company’s stock worth $116,000 after purchasing an additional 508 shares during the last quarter. Finally, TLP Group LLC increased its position in shares of Edwards Lifesciences by 163.6% during the 3rd quarter. TLP Group LLC now owns 680 shares of the medical research company’s stock worth $118,000 after purchasing an additional 422 shares during the last quarter. 81.27% of the stock is owned by institutional investors and hedge funds.

Shares of Edwards Lifesciences stock opened at $162.01 on Friday. Edwards Lifesciences Corp has a 12 month low of $110.68 and a 12 month high of $175.00. The stock has a market cap of $33.87 billion, a P/E ratio of 36.24, a PEG ratio of 2.13 and a beta of 0.87. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.31 and a quick ratio of 1.85.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, October 23rd. The medical research company reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.05. Edwards Lifesciences had a return on equity of 30.11% and a net margin of 20.67%. The company had revenue of $906.60 million during the quarter, compared to analysts’ expectations of $927.56 million. During the same period last year, the business posted $0.84 EPS. Edwards Lifesciences’s revenue for the quarter was up 10.4% on a year-over-year basis. As a group, equities analysts expect that Edwards Lifesciences Corp will post 4.7 EPS for the current fiscal year.

A number of brokerages recently issued reports on EW. Bank of America downgraded Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research report on Tuesday, October 2nd. ValuEngine raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Wednesday, September 19th. Morgan Stanley raised their price objective on Edwards Lifesciences from $150.00 to $157.00 and gave the stock an “overweight” rating in a research report on Thursday, October 11th. SunTrust Banks cut their price objective on Edwards Lifesciences to $170.00 and set a “buy” rating for the company in a research report on Friday, August 10th. Finally, Guggenheim downgraded Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research report on Tuesday, October 2nd. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the stock. Edwards Lifesciences currently has a consensus rating of “Buy” and a consensus price target of $158.45.

In related news, CFO Scott B. Ullem sold 25,036 shares of the firm’s stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $140.04, for a total transaction of $3,506,041.44. Following the completion of the transaction, the chief financial officer now directly owns 41,019 shares in the company, valued at approximately $5,744,300.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Schack Wesley W. Von sold 1,319 shares of the firm’s stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $160.96, for a total value of $212,306.24. Following the transaction, the director now owns 2,134 shares of the company’s stock, valued at $343,488.64. The disclosure for this sale can be found here. Insiders have sold a total of 212,192 shares of company stock valued at $31,055,823 over the last 90 days. 1.84% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: This report was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2018/12/02/great-lakes-advisors-llc-sells-6000-shares-of-edwards-lifesciences-corp-ew.html.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Further Reading: How to Invest in the Dividend Aristocrat Index

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit